Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
96.930,30
-0,28%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Avenue Therapeutics Inc (ATXI) Avenue Therapeutics Inc (ATXI) Notizie

Avenue Therapeutics Inc

ATXI
1,71
-0,09 (-5,00%)
21 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
04/12/202423:13EDGAR2Form S-3 - Registration statement under Securities Act of..
29/11/202422:05EDGAR2Form 8-K - Current report
14/11/202422:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202422:10EDGAR2Form 8-K - Current report
14/11/202422:05GLOBEAvenue Therapeutics Reports Third Quarter 2024 Financial..
09/10/202414:30GLOBEAvenue Therapeutics to Participate in Maxim Group’s 2024..
27/9/202422:18EDGAR2Form 8-K - Current report
25/9/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/9/202414:30GLOBEAvenue Therapeutics to Participate in Upcoming Investor..
13/8/202422:05GLOBEFortress Biotech Reports Second Quarter 2024 Financial..
09/8/202422:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202422:13EDGAR2Form 8-K - Current report
09/8/202422:05GLOBEAvenue Therapeutics Reports Second Quarter 2024 Financial..
12/7/202422:09EDGAR2Form S-8 - Securities to be offered to employees in employee..
20/6/202414:30GLOBEAvenue Therapeutics to Present at the H.C. Wainwright 5th..
23/5/202414:30EDGAR2Form 8-K - Current report
16/5/202414:30GLOBEAvenue Therapeutics Announces Last Patient Last Visit in..
15/5/202415:01EDGAR2Form 8-K - Current report
15/5/202414:30GLOBEAvenue Therapeutics Reports First Quarter 2024 Financial..
13/5/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
10/5/202422:53EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/5/202422:52EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/4/202414:00GLOBEAvenue Therapeutics Announces Exercise of Warrants for $4.4..
24/4/202413:30GLOBEAvenue Therapeutics Announces Reverse Stock Split
25/3/202413:30GLOBEAvenue Therapeutics to Host Virtual Key Opinion Leader (KOL)..
18/3/202421:05GLOBEAvenue Therapeutics Reports Full Year 2023 Financial Results..
15/3/202413:15GLOBEAvenue Therapeutics Receives Positive Listing Determination..
11/3/202413:00GLOBEAvenue Therapeutics to Present BAER-101 Preclinical Data at..
08/3/202422:31EDGAR2Form PRE 14C - Other preliminary information statements
08/3/202422:15EDGAR2Form 8-K - Current report
22/2/202414:30GLOBEAvenue Therapeutics Announces Publication in Drug..
29/1/202414:00EDGAR2Form DEF 14C - Other definitive information statements
24/1/202422:11EDGAR2Form S-3 - Registration statement under Securities Act of..
17/1/202423:05EDGAR2Form PRE 14C - Other preliminary information statements
12/1/202412:01EDGAR2Form 8-K - Current report
11/1/202414:00GLOBEAvenue Therapeutics to Present at Sidoti January Micro-Cap..
08/1/202423:28EDGAR2Form 8-K - Current report
05/1/202415:15GLOBEAvenue Therapeutics Enters into Warrant Exercise..
04/1/202414:30GLOBEAvenue Therapeutics Reaches Final Agreement with the U.S...
02/1/202414:30GLOBEAvenue Therapeutics Announces Completion of Enrollment in..
Apertura: 1,80 Min: 1,7618 Max: 1,9096
Chiusura: 1,80

La tua Cronologia

NASDAQ
ATXI
Avenue Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network